Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to...
GIM Raises US$20 Million Series A as Agentic Investing Enters Live Execution
HONG KONG, BEIJING and SHANGHAI, July 9, 2026 /PRNewswire/ -- Grace Investment Machine ("GIM"), an AI-native investment technology company building agentic systems for capital markets, today announced the close of its US$20 million Series A...
Corti Unlocks "Surgical" AI Improvement, Outperforming Big Tech in Interpretability Benchmark
New "GIM" method tops MIB global leaderboard, offering the industry a scalable way to inspect and improve billion-parameter models. COPENHAGEN, Denmark and NEW YORK, Dec. 19, 2025 /PRNewswire/ -- Corti, a healthcare AI infrastructure company, today...